Merck & Company, Inc. with price, financials, news flow, and insider context in one page.
Merck & Company, Inc. is being tracked here through price action, operating context, and headline flow. This public page covers the latest market move, where MRK sits inside Healthcare and Drug Manufacturers - General, and the key financial markers that matter before moving into a fuller research workflow.
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.
This page is structured for research context, not a trade call. It gives you a clean read on where MRK sits in its range, what the last few quarters look like, and which headlines are shaping attention.
For position sizing, alerts, saved watchlists, and deeper analysis workflows, the next step is the logged-in Meridian workspace.
| Quarter | Revenue | Net income | Free cash flow |
|---|---|---|---|
| Q1 2026 | 16.29B | -4.24B | 2.93B |
| Q4 2025 | 16.4B | 2.96B | 1.82B |
| Q3 2025 | 17.28B | 5.79B | 6.84B |
| Q2 2025 | 15.81B | 4.43B | 2.53B |
This is Goldman's second downward revision in a week, which gives the cuts additional weight as a directional signal rather than a knee-jerk reaction. The bring-forward of Persian Gulf export norma...
On Monday, the Dow Jones Industrial Average climbed to new intraday and closing records on a potential deal between the U.S. and Iran.
See the next report date, earnings cadence, and reporting context.
Open a side-by-side comparison page to frame valuation and growth.
Read open desk notes tied to sectors, macro themes, and active names.
Learn the framework behind valuation, momentum, and risk before you act.
Merck & Company, Inc. (MRK) — questions investors ask
What is the current stock price of Merck & Company, Inc. (MRK)?
Merck & Company, Inc. (MRK) is trading at $114.90, down 3.49% in the latest session. The live price and one-year chart on this page update through the trading day.
What is Merck & Company, Inc.'s market capitalization?
Merck & Company, Inc. has a market capitalization of about 283.78B, derived from the latest share price and shares outstanding.
When is Merck & Company, Inc.'s next earnings date?
Merck & Company, Inc. is next expected to report earnings on Aug 4, 2026. The MRK earnings page tracks the estimate and reporting history.
What is Merck & Company, Inc.'s P/E ratio?
Merck & Company, Inc. trades at a forward price-to-earnings ratio of 12.01 — one measure of how the market is pricing its future earnings.
What is MRK's 52-week trading range?
Over the past 52 weeks, MRK has traded between $76.66 and $125.14.
What sector is Merck & Company, Inc. in?
Merck & Company, Inc. operates in the Healthcare sector, within the Drug Manufacturers - General industry.
Does Merck & Company, Inc. pay a dividend?
Merck & Company, Inc. currently carries a dividend yield of about 100.0%.
What is the analyst price target for MRK?
The mean analyst price target for MRK is $129.74, with an overall analyst view of Buy.
A public stock page should answer the first research questions before asking for a signup.
This MRK page is designed for public research utility. You can read the latest session move, check the one-year chart, review a compact financial table, scan recent headlines, and compare adjacent names without immediately moving into a gated dashboard.
The logged-in Meridian workflow goes further with saved watchlists, deeper analysis, alert routing, and recurring review systems. The public layer is meant to be credible and indexable on its own, not a hollow teaser page.